423 related articles for article (PubMed ID: 23744585)
21. Features of Epstein-Barr Virus and Cytomegalovirus Reactivation in Acute Leukemia Patients After Haplo-HCT With Myeloablative ATG-Containing Conditioning Regimen.
Ru Y; Zhu J; Song T; Ding Y; Zhu Z; Fan Y; Xu Y; Sun A; Qiu H; Jin Z; Tang X; Han Y; Fu C; Chen S; Ma X; Chen F; Chen J; Wu D
Front Cell Infect Microbiol; 2022; 12():865170. PubMed ID: 35651756
[TBL] [Abstract][Full Text] [Related]
22. Influence of donor KIR genotypes on reduced relapse risk in acute myelogenous leukemia after hematopoietic stem cell transplantation in patients with CMV reactivation.
Nakamura R; Gendzekhadze K; Palmer J; Tsai NC; Mokhtari S; Forman SJ; Zaia JA; Senitzer D; Marcucci G; Stein A
Leuk Res; 2019 Dec; 87():106230. PubMed ID: 31644966
[TBL] [Abstract][Full Text] [Related]
23. Early CMV-replication after allogeneic stem cell transplantation is associated with a reduced relapse risk in lymphoma.
Koldehoff M; Ross SR; Dührsen U; Beelen DW; Elmaagacli AH
Leuk Lymphoma; 2017 Apr; 58(4):822-833. PubMed ID: 27687578
[TBL] [Abstract][Full Text] [Related]
24. Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type.
Yokoyama H; Takenaka K; Nishida T; Seo S; Shinohara A; Uchida N; Tanaka M; Takahashi S; Onizuka M; Kozai Y; Yasuhiro S; Ozawa Y; Katsuoka Y; Doki N; Sawa M; Kimura T; Kanda J; Fukuda T; Atsuta Y; Nakasone H;
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1363-1370. PubMed ID: 32311477
[TBL] [Abstract][Full Text] [Related]
25. Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.
Koh H; Nakamae H; Hagihara K; Nakane T; Manabe M; Hayashi Y; Nishimoto M; Umemoto Y; Nakamae M; Hirose A; Inoue E; Inoue A; Yoshida M; Bingo M; Okamura H; Aimoto R; Aimoto M; Terada Y; Koh KR; Yamane T; Ohsawa M; Hino M
J Exp Clin Cancer Res; 2011 Apr; 30(1):36. PubMed ID: 21477348
[TBL] [Abstract][Full Text] [Related]
26. Use of the cytomegalovirus pp65 antigenemia assay for preemptive therapy in allogeneic hematopoietic stem cell transplantation: a real-world review.
Tan BH; Chlebicka NL; Low JG; Chong TY; Chan KP; Goh YT
Transpl Infect Dis; 2008 Oct; 10(5):325-32. PubMed ID: 18627578
[TBL] [Abstract][Full Text] [Related]
27. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase.
Goldman JM; Majhail NS; Klein JP; Wang Z; Sobocinski KA; Arora M; Horowitz MM; Rizzo JD
J Clin Oncol; 2010 Apr; 28(11):1888-95. PubMed ID: 20212247
[TBL] [Abstract][Full Text] [Related]
28. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
[TBL] [Abstract][Full Text] [Related]
29. Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients.
Elmaagacli AH; Steckel NK; Koldehoff M; Hegerfeldt Y; Trenschel R; Ditschkowski M; Christoph S; Gromke T; Kordelas L; Ottinger HD; Ross RS; Horn PA; Schnittger S; Beelen DW
Blood; 2011 Aug; 118(5):1402-12. PubMed ID: 21540462
[TBL] [Abstract][Full Text] [Related]
30. CMV reactivation is associated with a lower incidence of relapse after allo-SCT for CML.
Ito S; Pophali P; CO W; Koklanaris EK; Superata J; Fahle GA; Childs R; Battiwalla M; Barrett AJ
Bone Marrow Transplant; 2013 Oct; 48(10):1313-6. PubMed ID: 23562969
[TBL] [Abstract][Full Text] [Related]
31. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis.
Stern M; de Wreede LC; Brand R; van Biezen A; Dreger P; Mohty M; de Witte TM; Kröger N; Ruutu T
Leukemia; 2014 Nov; 28(11):2235-40. PubMed ID: 24781016
[TBL] [Abstract][Full Text] [Related]
32. Immune reconstitution after haematopoietic cell transplantation in children: immunophenotype analysis with regard to factors affecting the speed of recovery.
Kalwak K; Gorczyńska E; Toporski J; Turkiewicz D; Slociak M; Ussowicz M; Latos-Grazyńska E; Król M; Boguslawska-Jaworska J; Chybicka A
Br J Haematol; 2002 Jul; 118(1):74-89. PubMed ID: 12100130
[TBL] [Abstract][Full Text] [Related]
33. Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies.
Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
Ann Hematol; 2020 Aug; 99(8):1883-1893. PubMed ID: 32572523
[TBL] [Abstract][Full Text] [Related]
34. Effect of conditioning regimen intensity on CMV infection in allogeneic hematopoietic cell transplantation.
Nakamae H; Kirby KA; Sandmaier BM; Norasetthada L; Maloney DG; Maris MB; Davis C; Corey L; Storb R; Boeckh M
Biol Blood Marrow Transplant; 2009 Jun; 15(6):694-703. PubMed ID: 19450754
[TBL] [Abstract][Full Text] [Related]
35. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors.
Wakamatsu M; Terakura S; Ohashi K; Fukuda T; Ozawa Y; Kanamori H; Sawa M; Uchida N; Ota S; Matsushita A; Kanda Y; Nakamae H; Ichinohe T; Kato K; Murata M; Atsuta Y; Teshima T;
Blood Adv; 2019 Jan; 3(2):105-115. PubMed ID: 30626574
[TBL] [Abstract][Full Text] [Related]
36. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group.
Jacobsen N; Badsberg JH; Lönnqvist B; Ringdén O; Volin L; Rajantie J; Nikoskelainen J; Keiding N
Bone Marrow Transplant; 1990 Jun; 5(6):413-8. PubMed ID: 2164434
[TBL] [Abstract][Full Text] [Related]
37. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
[TBL] [Abstract][Full Text] [Related]
38. Early CMV replication and subsequent chronic GVHD have a significant anti-leukemic effect after allogeneic HSCT in acute myeloid leukemia.
Jang JE; Kim SJ; Cheong JW; Hyun SY; Kim YD; Kim YR; Kim JS; Min YH
Ann Hematol; 2015 Feb; 94(2):275-82. PubMed ID: 25135450
[TBL] [Abstract][Full Text] [Related]
39. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
[TBL] [Abstract][Full Text] [Related]
40. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation.
Baron F; Labopin M; Niederwieser D; Vigouroux S; Cornelissen JJ; Malm C; Vindelov LL; Blaise D; Janssen JJ; Petersen E; Socié G; Nagler A; Rocha V; Mohty M
Leukemia; 2012 Dec; 26(12):2462-8. PubMed ID: 22699419
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
